An application to use Letrozole (Bretra, Femara, Letrozole) as non-reimbursment has been rejected. The HIRA is receiving applications in advance for the use of non-reimbursement from the MFDS to prevent the use of drugs that lack medical grounds or are concerned about safety.

According to The HIRA's recent details of "disapproval of use for non reimbursement drugs," nine cases of non-approval, including Letrozole, have been added, bringing a total of 212 cases of non-approval.

The medical institutions prescribed Bretra, Femara and Letrozole applied to the HIRA to combine ovarian stimulation with reproductive gland stimulants for preservation of fertility in breast cancer patients, but wer